| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6645961 | MERCK SHARP DOHME | Dry granulation formulation for an HIV protease inhibitor |
Mar, 2018
(6 years ago) | |
| US6689761 | MERCK SHARP DOHME | Combination therapy for HIV infection |
Feb, 2021
(3 years ago) | |
Crixivan is owned by Merck Sharp Dohme.
Crixivan contains Indinavir Sulfate.
Crixivan has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Crixivan are:
- US6645961
- US6689761
Crixivan was authorised for market use on 19 April, 2000.
Crixivan is available in capsule;oral dosage forms.
Crixivan can be used as treating hiv infection with indinavir sulfate in combination with antiretroviral agents.
The generics of Crixivan are possible to be released after 10 February, 2021.
Drugs and Companies using INDINAVIR SULFATE ingredient
Market Authorisation Date: 19 April, 2000
Treatment: Treating hiv infection with indinavir sulfate in combination with antiretroviral agents
Dosage: CAPSULE;ORAL
More Information on Dosage
CRIXIVAN family patents
